The Fund aims to increase the value of the funds contributed by the shareholders. The Fund may invest worldwide, including emerging countries, equities, equity-like securities (e.g. ADRs) and equities in Chinese companies that are listed in Hong Kong. The fund manager invests primarily in stocks of companies whose operations are in the areas of biotechnology, pharmaceuticals and life sciences, and healthcare.